# A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence

> **NCT06851104** · PHASE2 · TERMINATED · sponsor: **Guangxi Medical University** · enrollment: 45 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Cadonilimab (AK104)

## Key facts

- **NCT ID:** NCT06851104
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-02-16
- **Primary completion:** 2025-09-15
- **Final completion:** 2025-12-31
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** The support from the relevant company was not obtained as planned
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06851104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06851104, "A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06851104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*